[A15-34] Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 01.12.2015
Project no.:
A15-34
Commission:
Commission awarded on 20.08.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-41 | Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-01 | Pertuzumab - Addendum to Commission A15-34 | Commission completed |
| A13-10 | Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A22-103 | Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-102 | Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2016-02-18 G-BA decision was published.